Page last updated: 2024-08-22

stavudine and Chronic Hepatitis B

stavudine has been researched along with Chronic Hepatitis B in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Belyhun, Y; Liebert, UG; Maier, M	1
Moreno, V; Valencia, ME	1
Emery, S; Hu, Z; Khabo, P; Maja, P; Manzini, P; Matchaba, G; Matthews, GV; Metcalf, J; Orsega, S; Pool, N; Sangweni, P	1

Trials

1 trial(s) available for stavudine and Chronic Hepatitis B

Article	Year
Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS (London, England), 2011, Sep-10, Volume: 25, Issue:14 Topics: Adult; Africa, Southern; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; CD4 Lymphocyte Count; Didanosine; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Stavudine; Treatment Outcome	2011

Article

Year

Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa.

AIDS (London, England), 2011, Sep-10, Volume: 25, Issue:14

Topics: Adult; Africa, Southern; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; CD4 Lymphocyte Count; Didanosine; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Stavudine; Treatment Outcome

2011

Other Studies

2 other study(ies) available for stavudine and Chronic Hepatitis B

Article	Year
HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia. Antiviral therapy, 2017, Volume: 22, Issue:2 Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Ethiopia; Female; Genetic Variation; Genome, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Immune Evasion; Lamivudine; Male; Mutation; Stavudine; Viral Load; Zidovudine	2017
[Atazanavir-induced nephrolithiasis]. Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:2 Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir	2009

Article

Year

HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.

Antiviral therapy, 2017, Volume: 22, Issue:2

Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Ethiopia; Female; Genetic Variation; Genome, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Immune Evasion; Lamivudine; Male; Mutation; Stavudine; Viral Load; Zidovudine

2017

[Atazanavir-induced nephrolithiasis].

Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:2

Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir

2009